Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.

Zang L, Liu Y, Geng J, Luo Y, Bian F, Lv X, Yang J, Liu J, Peng Y, Li Y, Sun Y, Bosch-Traberg H, Mu Y

Diabetes, obesity & metabolism20 May 2016Cited by 27 (Europe PMC)

PMID27060930PMCIDPMC5084818DOI10.1111/dom.12674PepBankPUB-27060930

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes on metformin, add-on liraglutide 1.8 mg lowered HbA1c more than sitagliptin at week 26.
In plain wordsIn Chinese adults with type 2 diabetes on metformin, liraglutide lowered HbA1c more than sitagliptin did.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change from baseline to week 26
Study
n = 368
Comparator
Sitagliptin
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · subcutaneous · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−1.65%
liraglutide 1.8 mg
HbA1c change
−0.98%
sitagliptin
Estimated treatment difference
−0.67%
liraglutide vs sitagliptin
Source sentences
Summary
Liraglutide was superior to sitagliptin in reducing HbA1c from baseline [8.1% (65 mmol/mol)] to 26 weeks, as evidenced by estimated mean HbA1c change of -1.65% (-18.07 mmol/mol) versus -0.98% (-10.72 mmol/mol), respectively [estimated treatment difference for liraglutide vs sitagliptin of -0.67% (95…
1 context sentence(design, population, supporting numbers)
Summary · context
This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184) or once-daily…
Report a problemFND-2706093001
02HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes on metformin, more patients reached the HbA1c target of below 7.0% with liraglutide than with sitagliptin.
In plain wordsIn Chinese adults with type 2 diabetes on metformin, more people reached the HbA1c target with liraglutide than with sitagliptin.
Peptide
Liraglutide
Outcome
IncreasePatients reaching HbA1c below 7.0%
Study
n = 368
Comparator
Sitagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Patients reaching HbA1c <7.0%
76.5%
liraglutide
Patients reaching HbA1c <7.0%
52.6%
sitagliptin
Source sentences
Summary
More patients receiving liraglutide (76.5%) than sitagliptin (52.6%) achieved the HbA1c target of <7.0% (53 mmol/mol) at week 26 [odds ratio 3.65 (95% CI 2.18, 6.12); p < 0.0001].
1 context sentence(design, population, supporting numbers)
Summary · context
This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184) or once-daily…
Report a problemFND-2706093002
03HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes on metformin, fasting plasma glucose fell more with liraglutide than with sitagliptin.
In plain wordsIn Chinese adults with type 2 diabetes on metformin, fasting blood glucose fell more with liraglutide than with sitagliptin.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose
Study
n = 368
Comparator
Sitagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Reductions in fasting plasma glucose, 7-point self-measured plasma glucose and body weight were greater with liraglutide than with sitagliptin (p < 0.0001 for all).
1 context sentence(design, population, supporting numbers)
Summary · context
This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184) or once-daily…
Report a problemFND-2706093003
04HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes on metformin, 7-point self-measured plasma glucose fell more with liraglutide than with sitagliptin.
In plain wordsIn Chinese adults with type 2 diabetes on metformin, home-measured blood glucose fell more with liraglutide than with sitagliptin.
Peptide
Liraglutide
Outcome
Decrease7-point self-measured plasma glucose
Study
n = 368
Comparator
Sitagliptin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Reductions in fasting plasma glucose, 7-point self-measured plasma glucose and body weight were greater with liraglutide than with sitagliptin (p < 0.0001 for all).
1 context sentence(design, population, supporting numbers)
Summary · context
This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184) or once-daily…
Report a problemFND-2706093004
05HumanRandomized controlled trialEfficacy outcome
In Chinese adults with type 2 diabetes on metformin, body weight fell more with liraglutide than with sitagliptin.
In plain wordsIn Chinese adults with type 2 diabetes on metformin, body weight fell more with liraglutide than with sitagliptin.
Peptide
Liraglutide
Outcome
DecreaseBody weight reduction
Study
n = 368
Comparator
Sitagliptin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg · subcutaneous · 26 weeksAs given in this study (human).
Source sentences
Summary
Reductions in fasting plasma glucose, 7-point self-measured plasma glucose and body weight were greater with liraglutide than with sitagliptin (p < 0.0001 for all).
1 context sentence(design, population, supporting numbers)
Summary · context
This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184) or once-daily…
Report a problemFND-2706093005
06HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes on metformin, more patients had nausea with liraglutide than with sitagliptin.
In plain wordsIn Chinese adults with type 2 diabetes on metformin, more people felt nausea with liraglutide than with sitagliptin.
Peptide
Liraglutide
Outcome
IncreaseNausea
Study
n = 368
Comparator
Sitagliptin
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.8 mg · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Nausea
14.8%
liraglutide
Nausea
0.5%
sitagliptin
Source sentences
Summary
More patients experienced nausea (14.8% vs 0.5%), diarrhoea (8.2% vs 2.2%) and decreased appetite (10.9% vs 0.5%) with liraglutide than sitagliptin.
1 context sentence(design, population, supporting numbers)
Summary · context
This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184) or once-daily…
Report a problemFND-2706093006
07HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes on metformin, more patients had diarrhoea with liraglutide than with sitagliptin.
In plain wordsIn Chinese adults with type 2 diabetes on metformin, more people had diarrhoea with liraglutide than with sitagliptin.
Peptide
Liraglutide
Outcome
IncreaseDiarrhoea
Study
n = 368
Comparator
Sitagliptin
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.8 mg · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Diarrhoea
8.2%
liraglutide
Diarrhoea
2.2%
sitagliptin
Source sentences
Summary
More patients experienced nausea (14.8% vs 0.5%), diarrhoea (8.2% vs 2.2%) and decreased appetite (10.9% vs 0.5%) with liraglutide than sitagliptin.
1 context sentence(design, population, supporting numbers)
Summary · context
This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184) or once-daily…
Report a problemFND-2706093007
08HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes on metformin, more patients had decreased appetite with liraglutide than with sitagliptin.
In plain wordsIn Chinese adults with type 2 diabetes on metformin, more people had a lower appetite with liraglutide than with sitagliptin.
Peptide
Liraglutide
Outcome
IncreaseDecreased appetite
Study
n = 368
Comparator
Sitagliptin
Outcome group
Appetite and food intake · Gastrointestinal
Studied dose
1.8 mg · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Decreased appetite
10.9%
liraglutide
Decreased appetite
0.5%
sitagliptin
Source sentences
Summary
More patients experienced nausea (14.8% vs 0.5%), diarrhoea (8.2% vs 2.2%) and decreased appetite (10.9% vs 0.5%) with liraglutide than sitagliptin.
1 context sentence(design, population, supporting numbers)
Summary · context
This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184) or once-daily…
Report a problemFND-2706093008
09HumanRandomized controlled trialSafety outcome
In Chinese adults with type 2 diabetes on metformin, two hypoglycaemic episodes were confirmed with liraglutide and one with sitagliptin; none were severe or nocturnal.
In plain wordsIn Chinese adults with type 2 diabetes on metformin, two low blood sugar episodes were confirmed with liraglutide and one with sitagliptin; none were severe.
Peptide
Liraglutide
Outcome
Not applicableConfirmed hypoglycaemic episodes
Study
n = 368
Comparator
Sitagliptin
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.8 mg · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Confirmed hypoglycaemic episodes
2 episodes
liraglutide
Confirmed hypoglycaemic episodes
1 episodes
sitagliptin
Source sentences
Summary
Two hypoglycaemic episodes were confirmed for liraglutide and one for sitagliptin; none were severe or nocturnal.
1 context sentence(design, population, supporting numbers)
Summary · context
This 26-week open-label, active comparator trial (NCT02008682) randomized patients (aged 18-80 years) with T2DM inadequately controlled with metformin [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)] 1 : 1 to once-daily subcutaneously administered liraglutide 1.8 mg (n = 184) or once-daily…
Report a problemFND-2706093009

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT02008682

The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 368Dec 2013 to Nov 2014

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 9 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.